Allurion Technologies, Inc. reported a significant decline in financial performance for the first quarter of 2025, with revenues totaling $5.6 million, a decrease of 41% from $9.4 million in the same period of 2024. The company attributed this drop primarily to the suspension of sales in France, which had previously generated $1.7 million in revenue during the first quarter of 2024. Despite the revenue decline, Allurion achieved a net income of $7.4 million, compared to $5.6 million in the prior year, largely due to favorable changes in the fair value of its financial instruments, including warrants and convertible debt.
Operating expenses also decreased significantly, totaling $11.4 million for the first quarter of 2025, down from $18.3 million in the previous year. This reduction was driven by lower sales and marketing expenses, which fell by 41% to $3.6 million, and a 54% decrease in research and development costs to $2.6 million. The company has been restructuring its operations, which has led to a reduction in headcount and a shift in its sales strategy from business-to-business to a more consumer-focused approach.
Allurion's operational metrics indicate a strategic shift, with the company focusing on enhancing its product offerings and expanding its market presence. The Allurion Balloon, a swallowable intragastric balloon for weight loss, remains central to its business model, supported by the Allurion Virtual Care Suite, which provides remote patient monitoring and support. The company markets its products in over 50 countries and has recently resumed sales in France after regulatory approval was granted in February 2025.
Looking ahead, Allurion anticipates continued operating losses as it invests in regulatory approvals and product development. The company reported an accumulated deficit of $231.6 million as of March 31, 2025, and expects to rely on equity and debt financing to support its operations. The management has expressed concerns about its ability to maintain compliance with financial covenants and the potential need for additional capital, which could impact its operational strategies moving forward.
About ALLURION TECHNOLOGIES, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.